Europe:+32-2-535-7543
Asia: +65-6223-2436
Int'l: +1-860-674-8796
US: +1-866-353-3335
Cover Image

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2015 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2015 14
    • 2.2.1 LabCorp Raises USD2.9 Billion in Public Offering Notes 14
    • 2.2.2 AmerisourceBergen Acquires MWI Veterinary Supply for USD2.45 Billion 14
    • 2.2.3 Hubei Biocause Pharma Raises USD1.6 Billion in Private Placement of Shares 16
    • 2.2.4 Torrent Pharma Plans Private Placement of Bonds for USD1.22 Billion 16
    • 2.2.5 Endo International Prices Private Placement of 6% Notes Due 2014 for USD1.2 Billion 16
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2015 17
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2015 18

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, December 2014 19
    • 3.1.1 Top M&A Deals in January 2015 20
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2014 - January 2015 21
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2015 23
    • 3.2.1 Top Equity Offering Deals in January 2015 24
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2014 - January 2015 25
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2015 26
    • 3.3.1 Top PE/VC Deals in January 2015 27
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2015 28
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2015 29
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2014-January 2015 31
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2014-January 2015 32

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2015 33

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2015 33
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2014 - January 2015 35
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2015 36
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2015 37
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 38
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2014 - January 2015 40
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2014 - January 2015 41
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 43

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2015 45

  • 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2015 45
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2015 47
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2015 48
    • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2015 49
    • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2015 49
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2014 - January 2015 50
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2014 - January 2015 51
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2014 - January 2015 53
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2014 - January 2015 55

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 57

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2015 57
    • 6.1.1 Oncology - Deals of the Month 58
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2015 62
    • 6.2.1 Central Nervous System - Deals of the Month 63
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2015 65
    • 6.3.1 Infectious Diseases - Deals of the Month 67
  • 6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2015 69
    • 6.4.1 Cardiovascular - Deals of the Month 70
  • 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2015 72
    • 6.5.1 Immunology - Deal of the Month 73
  • 6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, January 2015 75
    • 6.6.1 Gastrointestinal - Deals of the Month 76
  • 6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, January 2015 78
    • 6.7.1 Metabolic Disorders - Deal of the Month 79

7 Deal Summary by Geography 81

  • 7.1 Pharmaceuticals & Healthcare, North America Deals, January 2015 81
    • 7.1.1 North America - Deals of the Month 82
  • 7.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2015 86
    • 7.2.1 Europe - Deals of the Month 87
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2015 89
    • 7.3.1 Asia-Pacific - Deals of the Month 91
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2015 92
    • 7.4.1 Rest of the World - Deals of the Month 93

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 94

  • 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2014 - January 2015 94
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2014 - January 2015 96

9 Further Information 98

  • 9.1 Methodology 98
  • 9.2 About GlobalData 99
  • 9.3 Disclosure information 100
  • 9.4 Disclaimer 100

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, December 2014 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2015 18
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 20
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2015 20
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2014 - January 2015 22
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 24
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2015 24
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 25
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 27
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2015 27
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2014 - January 2015 29
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2015 30
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 31
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2014 - January 2015 32
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 34
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 35
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 36
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2015 37
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 39
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 - January 2015 42
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2014 - January 2015 44
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 46
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 48
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2015 48
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2015 49
  • Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2015 49
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 50
  • Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2015 52
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 - January 2015 54
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2015 56
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 58
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 63
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 66
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 70
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 73
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 76
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 79
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 82
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 87
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 90
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 93
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 95
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 97

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%),January 2015 17
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2015 18
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 19
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2014 - January 2015 21
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 23
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 25
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 26
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2014 - January 2015 28
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2015 29
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2015 30
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 31
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 33
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 35
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 36
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 38
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 - January 2015 40
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 - January 2015 41
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 43
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 45
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 47
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 50
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 - January 2015 51
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2014 - January 2015 53
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2014 - January 2015 54
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2015 55
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 57
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 62
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 65
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 69
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 72
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 75
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 78
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 81
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 86
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 89
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 92
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 94
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2014 - January 2015 96
Show More
Pricing
Back to Top